Reportlinker Adds Global Anti-Migraine Drugs Industry

NEW YORK, March 9 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Anti-Migraine Drugs Industry

http://www.reportlinker.com/p0181096/Global-Anti-Migraine-Drugs-Industry.html

This report analyzes the US And European markets for Anti-Migraine Drugs in US$ Million. Annual forecasts are provided for the period 2006 through 2015. A six-year historic Analysis is also provided for these markets. The report profiles 53 companies including many key and niche players such as Abbott Laboratories, Inc., Eisai, Inc., Eisai, Inc, Johnson & Johnson, Inc., Kowa Pharmaceuticals America, Inc., MAP Pharmaceuticals, Inc., Merck & Co., Inc., Merck & Co., Inc., Poze, Poze., Winston Pharmaceuticals, Inc., Wyeth Consumer Healthcare, Zogenix, Inc., AstraZeneca Plc, Bayer AG, Ethypharm S.A., GlaxoSmithKline Plc, Meda AB, Novartis AG, and Novartis AG. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

ANTI-MIGRAINE DRUGS MCP-6126

A US AND EUROPEAN MARKET REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability And Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-3

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

II-A. A US AND EUROPEAN MARKET REPORT

1. MIGRAINE: AN OVERVIEW II-1

What is Migraine? II-1

What Causes Migraine? II-1

Migraine Classification II-2

Migraine with Aura II-2

Migraine without Aura II-2

Aura without Headache II-2

Abdominal Migraine II-2

Facial Migraine II-3

Basilar Migraine II-3

Familial Hemiplegic Migraine II-3

Ophthalmoplegic/Ocular Migraine II-3

Retinal Migraine II-3

Menstrual Migraine II-3

Status Migraine II-4

Migraine Attack Stages II-4

I - The Prodrome Stage II-4

II - The Aura Stage II-4

III - The Headache Stage II-4

IV - The Postdrome Stage II-5

2. ANTI-MIGRAINE TREATMENT II-6

Historical Perspective II-6

Migraine Treatment II-6

Abortive Drugs II-6

Selective Serotonin Receptor (5- HTI) Agonists/ Triptans II-7

Triptans Approved for the Treatment of Migraine II-7

Ergot Alkaloids II-7

Ergot Alkaloids for the Treatment of Migraine II-8

Antiemetics II-8

Antiemetics for the Treatment of Migraine II-8

Analgesics II-8

Analgesics for the Treatment of Migraine II-9

Prophylactic Drugs II-10

Beta-Blockers II-10

Calcium Channel Blockers II-10

Anticonvulsants II-10

Tricyclic Antidepressants II-11

Non-steroidal Anti-inflammatory Drugs II-11

Selective Serotonin Reuptake Inhibitors II-11

Serotonin Antagonists II-11

Anti-migraine Drugs: Side Effects II-11

Abortive Drugs: Side Effects II-12

Prophylactic Drugs: Side Effects II-12

Anti-migraine Drugs: Interactions II-13

Abortive Medications: Interactions II-13

Prophylactic Drugs: Interactions II-14

3. RESEARCH & DEVELOPMENT II-15

Pipeline Drug Research II-15

Pipeline Drug Candidates in Phase III Clinical Trials II-15

Pipeline Drug Candidates in Phase II Clinical Trials II-15

Clinical Research / Drug Development Initiatives II-15

MAP Pharma Announces Positive Phase III Results for Levadex II-15

Addex Initiates Phase IIb Trials for ADX 10059 II-16

Asterand and BTG Announce Plans to Commence Phase IIa Trials II-16

Alexza Commences Phase IIb Trials of AZ-104 II-16

Neuralieve Announces Trial Completion of New Migraine

Treatment Device II-16

NeurAxon Announces Encouraging Results of Phase 2 Trials II-17

Roxro Pharma Announces ROX-828 Results II-17

Merck Announces Encouraging Results of Phase III Study of

Telcagepant II-17

ProEthic Pharmaceuticals Reports Encouraging Phase III Results II-18

Recent Migraine Research II-18

Study Reveals Cocoa Consumption to Ease Migraine II-18

Study Reveals Women with Migraine to be At Lesser Risk of

Breast Cancer II-18

Study Shows Risk of Migraine to be Less Among High Blood

Pressure Patients II-18

II-B. REGIONAL MARKET PERSPECTIVE

1. THE UNITED STATES II-19

A.Market Analysis II-19

Current & Future Analysis II-19

Historic Analysis II-19

Migraine - Prevalence and Economic Burden II-19

Anti-Migraine Drugs Market At A Glance II-19

Triptans - Leading the Anti-Migraine Treatment Race II-20

Generic Imitrex Make Foray II-20

Botox - An Emerging Option for Migraine Prophylaxis II-21

Anti-migraine Drugs - Limitations Abound II-21

The Quest to Unravel the Mystery of Cause of Migraine

Continues II-21

Strategic Corporate Developments II-22

Zogenix, Astellas Pharma Sign Agreement for Sumavel DosePro II-22

Kowa Pharma to Divest Diclofenac Franchise II-22

Zogenix Wins FDA Approval for Sumavel DosePro II-22

Orchid Pharma Obtains FDA Approval for Sumatriptan

Succinate Tablets II-23

Sandoz Unveils Sumatriptan and Calcitonin- Salmon Nasal Spray II-23

Wockhardt to Introduce Divalproex ER II-23

Ranbaxy Receives FDA Approval for Imitrex Generic II-23

Kowa America Secures FDA Approval for Cambia II-24

Almirall Receives FDA Approval for Axert/ Almogran II-24

Wockhardt Receives FDA Approval for Sumatriptan Injections II-24

Teva Pharmaceutical Secures Approval, Launches Imitrex

Generic II-24

AstraZeneca Unveils Zomig Rapimeltt in 5 mg Dosage Strength II-24

Bedford Laboratories Launches Sumatriptan Succinate Injection II-25

Ipca Laboratories and Heritage Pharmaceuticals Announce

Strategic Alliance II-25

Dr. Reddy's Introduces Approved Imitrex® Generic II-25

US FDA Approves Divalproex Sodium Tablets II-25

GSK and Pozen Announce FDA Approval for Treximet II-26

Aurobindo Wins Provisionary Approval for Sumatriptan

Succinate Tablets II-26

Par Pharmaceuticals to Commence Shipment of Imitrex's

Generic Version II-26

Select Players II-26

Abbott Laboratories, Inc. II-26

Eisai, Inc. II-27

Eli Lilly and Company II-28

Johnson & Johnson, Inc. II-28

Kowa Pharmaceuticals America, Inc. II-29

MAP Pharmaceuticals, Inc. II-29

Merck & Co., Inc. II-29

Pfizer, Inc. II-30

Pozen II-30

Roxro Pharma, Inc. II-31

Winston Pharmaceuticals, Inc. II-31

Wyeth Consumer Healthcare II-31

Zogenix, Inc. II-32

B.Market Analytics II-32

Table 1: US Recent Past, Current & Future Analysis for

Anti-Migraine Drugs - Annual Sales Figures in US$ Million

for Years 2007 through 2015 (includes corresponding

Graph/Chart) II-32

Table 2: US Historic Analysis for Anti-Migraine Drugs -

Annual Sales Figures in US$ Million for Years 2001 through

2006 (includes corresponding Graph/Chart) II-33

2. EUROPE II-34

A.Market Analysis II-34

Current & Future Analysis II-34

Historic Analysis II-34

Strategic Corporate Developments II-34

Orexo Acquires PharmaKodex II-34

Noxxon Pharma Collaborates with Eli Lilly II-35

Select Players II-35

AstraZeneca Plc (UK) II-35

Bayer AG (Germany) II-35

Ethypharm S.A. (France) II-36

GlaxoSmithKline Plc (UK) II-36

Meda AB (Sweden) II-37

Novartis AG (Switzerland) II-37

UCB S.A. (Belgium) II-37

B.Market Analytics II-38

Table 3: European Recent Past, Current & Future Analysis for

Anti-Migraine Drugs by Region - France, Germany, Italy, UK,

Spain and Rest of Europe Markets Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2007 through

2015 (includes corresponding Graph/Chart) II-38

Table 4: European Historic Analysis for Anti-Migraine Drugs

by Region - France, Germany, Italy, UK, Spain and Rest of

Europe Markets Independently Analyzed with Annual Sales

Figure in US$ Million for Years 2001 through 2006 (includes

corresponding Graph/Chart) II-39

Table 5: European 15-year Perspective for Anti-Migraine

Drugs by Region - Percentage Breakdown of Value Sales for

France, Germany, Italy, UK, Spain and Rest of Europe Markets

for Years 2003, 2009 & 2015 (includes corresponding

Graph/Chart) II-40

2a. FRANCE II-41

A.Market Analysis II-41

Current & Future Analysis II-41

Historic Analysis II-41

B.Market Analytics II-41

Table 6: French Recent Past, Current & Future Analysis for

Anti-Migraine Drugs -Annual Sales Figures in US$ Million for

Years 2007 through 2015 (includes corresponding Graph/Chart) II-41

Table 7: French Historic Analysis for Anti-Migraine Drugs -

Annual Sales Figures in US$ Million for Years 2001 through

2006 (includes corresponding Graph/Chart) II-42

2b. GERMANY II-43

A.Market Analysis II-43

Current & Future Analysis II-43

Historic Analysis II-43

B.Market Analytics II-43

Table 8: German Recent Past, Current & Future Analysis for

Anti-Migraine Drugs - Annual Sales Figures in US$ Million

for Years 2007 through 2015 (includes corresponding

Graph/Chart) II-43

Table 9: German Historic Analysis for Anti-Migraine Drugs -

Annual Sales Figures in US$ Million for Years 2001 through

2006 (includes corresponding Graph/Chart) II-44

2c. ITALY II-45

A.Market Analysis II-45

Current & Future Analysis II-45

Historic Analysis II-45

B.Market Analytics II-45

Table 10: Italian Recent Past, Current & Future Analysis for

Anti-Migraine Drugs -Annual Sales Figures in US$ Million for

Years 2007 through 2015 (includes corresponding Graph/Chart) II-45

Table 11: Italian Historic Analysis for Anti-Migraine Drugs

- Annual Sales Figures in US$ Million for Years 2001 through

2006 (includes corresponding Graph/Chart) II-46

2d. UNITED KINGDOM II-47

A.Market Analysis II-47

Current & Future Analysis II-47

Historic Analysis II-47

Migraine - Prevalence II-47

Migraine Treatment II-47

Abortive Drugs II-47

List of Abortive Anti-Migraine Drugs Available in the UK II-48

Prophylactic Drugs II-48

List of Prophylactic Anti-Migraine Drugs Available in the UK II-49

B.Market Analytics II-49

Table 12: UK Recent Past, Current & Future Analysis for

Anti-Migraine Drugs -Annual Sales Figures in US$ Million for

Years 2007 through 2015 (includes corresponding Graph/Chart) II-49

Table 13: UK Historic Analysis for Anti-Migraine Drugs -

Annual Sales Figures in US$ Million for Years 2001 through

2006 (includes corresponding Graph/Chart) II-50

2e. SPAIN II-51

A.Market Analysis II-51

Current & Future Analysis II-51

Historic Analysis II-51

B.Market Analytics II-51

Table 14: Spanish Recent Past, Current & Future Analysis for

Anti-Migraine Drugs - Annual Sales Figures in US$ Million

for Years 2007 through 2015 (includes corresponding

Graph/Chart) II-51

Table 15: Spanish Historic Analysis for Anti-Migraine Drugs

- Annual Sales Figures in US$ Million for Years 2001 through

2006 (includes corresponding Graph/Chart) II-52

2f. REST OF EUROPE II-53

A.Market Analysis II-53

Current & Future Analysis II-53

Historic Analysis II-53

Ireland II-53

B.Market Analytics II-54

Table 16: Rest of Europe Recent Past, Current & Future

Analysis for Anti-Migraine Drugs -Annual Sales Figures in

US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) II-54

Table 17: Rest of Europe Historic Analysis for Anti-

Migraine Drugs - Annual Sales Figures in US$ Million for

Years 2001 through 2006 (includes corresponding Graph/Chart) II-54

III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 53 (including Divisions/Subsidiaries - 57)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 24

Canada 2

Japan 5

Europe 16

Germany 2

The United Kingdom 5

Italy 2

Spain 1

Rest of Europe 6

Asia-Pacific (Excluding Japan) 9

Middle-East 1

------------------------------------------

To order this report:

Drug and Medication Industry: Global Anti-Migraine Drugs Industry

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker